As COVID-19 vaccines become more and more available across the country, and COVID infection rates are generally on the decline, there’s no shortage of questions about how those vaccines may…
As COVID-19 vaccines become more and more available across the country, and COVID infection rates are generally on the decline, there’s no shortage of questions about how those vaccines may…
Like with all habits, it helps to start small. Try something new that you’ve always been curious about or interested in learning more about. Starting small could mean taking a…
Here’s a compilation of some fun and free apps to inspire creativity or provide tools to create! Happy Color: A great app for creating and coloring pictures. Especially helpful you have…
Expanding our understanding of creativity, why it’s important for our health and well-being, and how it can help us navigate challenging times. When we first see the word “creativity” in…
The following is a current chart of disease modifying therapies approved for the treatment of multiple sclerosis, as of November 2020. Reviewed by Rocky Mountain MS Center Medical Director Dr….
EDITOR’S NOTE: Information contained in this article is current as of the time of printing, Nov. 25, 2020. Despite months of precautions, warnings and official guidelines, the COVID-19 pandemic is…
A Lifelong Practice for Coping with Stress and Anxiety As we reflect on the past year, some words and emotions are likely to surface for many of us right away:…
A Look at Current Research Priorities at the Rocky Mountain MS Center at University of Colorado The Rocky Mountain MS Center at University of Colorado is the home of one…
It’s no secret that many of the most commonly-prescribed MS treatments can be expensive, making access to them difficult for some people living with MS. Understanding this, many pharmaceutical companies…
Individualizing treatment according to a patient’s risk profile starting with high-efficacy treatments helps prevent irreversible brain and spinal cord damage, thus leading to better outcomes. First Line: Natalizumab (Tysabri) in JCV…